J&J ends a sickle cell collaboration with Icagen

Shares of Icagen slipped this morning after a J&J subsidiary announced it was canceling a pact to develop a new therapy for sickle cell disease. The announcement terminates the pharma giant's commitment to paying up to $48 million in milestones for the successful development of senicapoc. But it couldn't have been a big surprise to investors. Clinical trials of the therapy ended last April when it proved ineffective in halting the pain spurred by the disease.

- check out the release
- here's the report from TechJournal South

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.